Work Here?
Overview
Evio partners with health plans to improve access to medications for patients, providers, and the health system by using real-world evidence to ensure the right medication is prescribed and affordable. It works by aligning data, care teams, and benefit design within payer and provider workflows to streamline the medication journey. Compared to competitors, Evio ties real-world data to payer and provider processes and emphasizes affordability and appropriate prescribing across the medication continuum. Its goal is to make the medication experience safer, easier to navigate, and cheaper while reducing waste in healthcare.
About Evio
Industries
Data & Analytics
Consulting
Enterprise Software
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
Costa Mesa, California
Founded
2011
Get referred to Evio
See people who can refer or advise you
Simplify's Take
What believers are saying
- October 2024 adalimumab biosimilar deal proves Evio can negotiate lower-cost access.
- March 2025 Wellmark investment validates the company after four years without new owners.
- Evio's 2026 site highlights manufacturer-focused offerings, expanding revenue beyond payer contracts.
What critics are saying
- Evio sued Pfizer in August 2023; contract disputes drain management and legal budget.
- Flipt powers Evio's platform; vendor dependence creates switching and integration risk by 2026.
- If biosimilar savings stall, owner plans abandon Evio's model and shrink it fast.
What makes Evio unique
- Evio Access, launched February 2025, combines manufacturer contracting, market intelligence, and pull-through.
- Its Aetion partnership analyzes over 1 billion claims across 35 million lives.
- Wellmark joined March 2025, giving Evio a sixth owner health plan.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401K Company Match
Unlimited Paid Time Off
Parental Leave
Company News
DENVER, March 6, 2025 /PRNewswire/ -- Evio Pharmacy Solutions proudly announces the addition of Wellmark Blue Cross and Blue Shield as its sixth investor and owner health plan. This new partnership is an exciting development for Evio as the company welcomes its first new investor since its establishment four years ago.Wellmark, a member-owned independent licensee of the Blue Cross Blue Shield Association, serves more than two million people in Iowa and South Dakota. Wellmark, known for its innovative approaches and commitment to making health care better, will further Evio's mission to deliver differentiated pharmacy care.Evio works with health plans to transform the medication experience for everyone: patients, providers, employers, and the pharmacy system at large. Utilizing real-world evidence analytics, innovative medication contracting models, and a suite of digital tools, Evio aims to ensure every patient can access the right medication for their unique situation, from the beginning, in a simple and affordable way."Our board and I are thrilled to welcome Wellmark to help drive our transformative agenda," said Hank Schlissberg, chief executive officer of Evio. "Having established a compelling vision, a phenomenal team, and a track record of measurable impact, Evio was open to new partners for the first time. When we evaluated potential additions, Wellmark quickly rose to the top
Blue Shield is teaming up with drugmaker Fresenius Kabi and Evio Pharmacy Solutions to purchase a biosimilar for Humira at a transparent net price of $525 per monthly dose.
Blue Shield's agreement with drug manufacturer Fresenius Kabi, an operating company of Fresenius, and Evio Pharmacy Solutions, which facilitated the deal, introduces a new model called Pharmacy Care Reimagined.
DENVER, Oct. 1, 2024 /PRNewswire/ -- Evio Pharmacy Solutions, a Blues-founded company focused on transformational solutions in the high-cost medication space, today announced the successful negotiation and implementation of an innovative direct purchase agreement with Fresenius Kabi, an operating company of Fresenius, for Adalimumab-aacf — a lower priced biosimilar version of Humira. Humira is one of the most widely prescribed and, at more than $12 billion annually, the highest revenue producing medication in the United States. This landmark direct purchase agreement creates a transparent, alternative business model that makes a highly effective treatment accessible to Evio owner health plans and their members at a lower cost. Biosimilars are low-cost biologic medications highly similar to an already approved reference product. They have been rigorously tested and have demonstrated the same clinical benefit and safety as the original product
To increase price transparency, Evio Pharmacy Solutions, part of BCBS Michigan, has partnered with Flipt.
Evio is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Evio
Industries
Data & Analytics
Consulting
Enterprise Software
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
Costa Mesa, California
Founded
2011
Evio is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today